Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
Scribe Therapeutics Inc.
Market Cap
$267.00M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.62M
Return on Equity (ROE)
-430.72%
TTM Avg
122.09%
3Y Avg
211.60%
5Y Avg
136.09%
Market Cap
$269.77M
Return on Equity (ROE)
-5.95%
TTM Avg
-61.29%
3Y Avg
-64.14%
5Y Avg
-41.58%
Market Cap
$269.87M
Return on Equity (ROE)
-87.86%
TTM Avg
-58.47%
3Y Avg
-55.90%
5Y Avg
-119.72%
Market Cap
$270.01M
Return on Equity (ROE)
-124.83%
TTM Avg
-35.45%
3Y Avg
-17.31%
5Y Avg
-9.59%
Market Cap
$270.25M
Return on Equity (ROE)
-4.68%
TTM Avg
-68.17%
3Y Avg
-57.88%
5Y Avg
-49.64%
Market Cap
$263.68M
Return on Equity (ROE)
-184.27%
TTM Avg
-57.34%
3Y Avg
-61.84%
5Y Avg
-87.31%
Market Cap
$262.66M
Return on Equity (ROE)
-15.46%
TTM Avg
-12.46%
3Y Avg
-4.29%
5Y Avg
-4.49%
Market Cap
$262.92M
Return on Equity (ROE)
-39.55%
TTM Avg
-28.46%
3Y Avg
-79.02%
5Y Avg
-63.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $267.00M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.62M | -430.72% | 122.09% | 211.60% | 136.09% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $269.77M | -5.95% | -61.29% | -64.14% | -41.58% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $269.87M | -87.86% | -58.47% | -55.90% | -119.72% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.01M | -124.83% | -35.45% | -17.31% | -9.59% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.25M | -4.68% | -68.17% | -57.88% | -49.64% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $263.68M | -184.27% | -57.34% | -61.84% | -87.31% |
| OraSure Technologies, Inc. (OSUR)vs › | $262.66M | -15.46% | -12.46% | -4.29% | -4.49% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.92M | -39.55% | -28.46% | -79.02% | -63.95% |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | -82.12% | -62.12% | -56.53% | -50.41% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
